Faculty of Medicine, Clinicum, Translational Immunology Research Program, Research Program Unit (RPU), University of Helsinki (UH), 00014 Helsinki, Finland.
Systems Biology/Pathology Research Group, iCAN Digital Precision Cancer Medicine Flagship, Institute of Biotechnology, HiLIFE, UH, 00014 Helsinki, Finland.
Cell Rep Med. 2024 Apr 16;5(4):101503. doi: 10.1016/j.xcrm.2024.101503. Epub 2024 Apr 8.
In monogenic autoinflammatory diseases, mutations in genes regulating innate immune responses often lead to uncontrolled activation of inflammasome pathways or the type I interferon (IFN-I) response. We describe a mechanism of autoinflammation potentially predisposing patients to life-threatening necrotizing soft tissue inflammation. Six unrelated families are identified in which affected members present with necrotizing fasciitis or severe soft tissue inflammations. Exome sequencing reveals truncating monoallelic loss-of-function variants of nuclear factor κ light-chain enhancer of activated B cells (NFKB1) in affected patients. In patients' macrophages and in NFKB1-variant-bearing THP-1 cells, activation increases both interleukin (IL)-1β secretion and IFN-I signaling. Truncation of NF-κB1 impairs autophagy, accompanied by the accumulation of reactive oxygen species and reduced degradation of inflammasome receptor nucleotide-binding oligomerization domain, leucine-rich repeat-containing protein 3 (NLRP3), and Toll/IL-1 receptor domain-containing adaptor protein inducing IFN-β (TRIF), thus leading to combined excessive inflammasome and IFN-I activity. Many of the patients respond to anti-inflammatory treatment, and targeting IL-1β and/or IFN-I signaling could represent a therapeutic approach for these patients.
在单基因自身炎症性疾病中,调节先天免疫反应的基因发生突变,通常会导致炎症小体途径或 I 型干扰素(IFN-I)反应的失控激活。我们描述了一种自身炎症的潜在机制,可能使患者易患危及生命的坏死性软组织炎症。在六个无关联的家族中,发现受影响的成员出现坏死性筋膜炎或严重的软组织炎症。外显子组测序显示,受影响患者的核因子 κ 轻链增强子的激活 B 细胞(NFKB1)单等位基因截断失活变体。在患者的巨噬细胞和携带 NFKB1 变体的 THP-1 细胞中,激活增加了白细胞介素(IL)-1β的分泌和 IFN-I 信号。NF-κB1 的截断会损害自噬,同时伴有活性氧的积累和炎症小体受体核苷酸结合寡聚结构域、富含亮氨酸重复的蛋白 3(NLRP3)和 Toll/IL-1 受体域包含衔接蛋白诱导 IFN-β(TRIF)的降解减少,从而导致过度的炎症小体和 IFN-I 活性。许多患者对抗炎治疗有反应,针对 IL-1β 和/或 IFN-I 信号的治疗方法可能是这些患者的一种治疗选择。